Additionally, CYP2C8 and CYP3A4 are high involved in the metabolism of paclitaxel in patients with ovarian cancer (Bergmann et al., 2011), while breast cancer patients carrying the *3 variant of CYP2C8 have better response to paclitaxel, but at an increase in peripheral neurotoxicity (Hertz et al., 2012). This evidence concerns the gene CYP2C8 and ovarian cancer.